Using the Ocean to Suck Up CO2 Could Come With the Small, Unintended Side Effect of Wiping Out Marine Life
One of the most intriguing possibilities involves using the ocean, already the world's largest carbon sink, to suck up even more of the greenhouse gas by removing some of the carbon that it already stores.
Dozens of startups are already experimenting with this form of climate intervention, which is sometimes referred to as marine carbon dioxide removal. What makes it so appealing is that the ocean, in theory, would essentially do the work for us: all we'd have to do is set it into motion and store — or even repurpose — the extracted gases so they doesn't reenter the atmosphere.
But it may be too good to be true. In a new study published in the journal Environmental Research Letters, a team of international researchers warn that this could have dire unintended consequences — like accelerating the decline of the ocean's already plunging oxygen levels.
"What helps the climate is not automatically good for the ocean," lead author Andreas Oschlies, from the GEOMAR Helmholtz Center for Ocean Research Kiel in Germany, said in a statement about the work.
The warmer that water becomes, the less oxygen it can dissolve. In the past fifty years, as global temperatures steadily climbed, the ocean has lost nearly 2 percent of its total dissolved oxygen, a proportion roughly equal to a staggering 77 billion metric tons, according to a 2018 study.
At its worst, this phenomenon, known as ocean deoxygenation, creates entire "dead zones" where there's so little oxygen available that the waters become virtually uninhabitable. Sometimes stretching across thousands of square miles, whatever marine life was once living in the afflicted area either flees or, more grimly, suffocates to death.
Climate change has accelerated the eerie aquatic trend, increasing both the size and number of these dead zones. Clearly, halting global warming would help stymy this — but not if the solution we employ requires putting additional strain on the ocean. In particular, it appears that biotic forms of marine carbon removal could precipitate devastating losses of dissolved oxygen, the researchers caution.
One leading method, called ocean fertilization, proposes seeding the seas with nutrients to boost the growth of oxygen-producing algae. The problem is that when the phytoplanktons perish, their tiny corpses sink to the ocean floor, where the bacteria that feed on them end up consuming even more oxygen.
"Methods that increase biomass production in the ocean, and subsequently lead to oxygen-consuming decomposition, cannot be considered harmless climate solutions," Oschlies said in the statement. "Our model simulations show that such approaches could cause a decrease in dissolved oxygen that is 4 to 40 times greater than the oxygen gain expected from reduced global warming."
But the researchers aren't advocating against using the ocean as a carbon sink entirely. Encouragingly, they found that abiotic methods, including one that involves flushing the waters with minerals like limestone to convert CO2 into a molecule that stays trapped underwater, has minimal effects on oxygen levels.
Instead, the researchers want to stress that going forward, anyone pursuing this research should put assessing the potential oxygen toll of their technique front and center.
"The ocean is a complex system which is already heavily under pressure," Oschlies said. "If we intervene with large-scale measures, we must ensure that, no matter how good our intentions are, we are not further threatening marine environmental conditions that marine life depends on."
More on the ocean: A Strange Darkness Is Spreading Throughout the Oceans
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
22 minutes ago
- Gizmodo
This Bright Dot May Be an Entirely New Type of Space Object
At first, the dot looked like any other star. Then the astrophysicists switched to polarized light and found themselves looking at an entirely unexpected sight. 'Everything else disappeared, even the bright central black hole, and only this little dot remained,' Elena Shablovinskaia, an astrophysicist at Universidad Diego Portales in Chile and the Max Planck Institute for Radio Astronomy in Germany, told Gizmodo. Shablovinskaia's team believes they've discovered an entirely new kind of space object, which they've dubbed 'Punctum.' Like its name, Latin for 'point' or 'dot,' Punctum is a compact, bright splotch of light in space—but it's only visible at millimeter wavelengths and harbors an unusually organized magnetic field. A paper on Punctum has been accepted for publication in Astronomy & Astrophysics and is currently available on arXiv. The team wanted to show that Punctum is simply an unusual example of a known phenomenon, such as a magnetar or a supernova remnant. NGC 4945, where Punctum lives, is a nearby galaxy known for hosting an active population of baby stars—so it made sense to assume Punctum was one of them. After all, NGC 4945 resides so close to the Milky Way that astrophysicists thought they had a solid grasp of the galaxy. We couldn't have missed something 'hiding in plain sight,' as Shablovinskaia put it…could we? But the more they tried to force Punctum into established astrophysical wisdom, the more it seemed to defy it. For example, Punctum disappeared when the team checked the same region using X-ray or radio telescopes, appearing only in the millimeter spectrum with the Atacama Large Millimeter/submillimeter Array (ALMA). ALMA's ability to capture polarized light also revealed Punctum's weird magnetic field to the scientists, adding to its mystery. Astronomers Calculate Universe's Age With Atacama Desert Telescope 'So we compared its brightness, polarization, and spectrum to every extreme object we could think of—magnetars, pulsars, star-forming regions, and black hole jets,' Shablovinskaia recalled. 'Nothing matched.' But accepting that they'd struck something entirely new only raised more questions. What exactly is it? Where does Punctum—10,000 to 100,000 times brighter than magnetars and 10 to 100 times brighter than most supernovas—get its light? Could it be connected to a black hole or a neutron star? For Shablovinskaia, the best shot at finding the answer might be to investigate Punctum's strange polarization, 'basically a fingerprint of the magnetic environment,' she said. After all, the disturbingly neat alignment of the light waves around Punctum was what alerted the team to the object's weirdness. 'Usually, when light is produced in cosmic environments, it comes out mixed and disordered because the magnetic fields are tangled,' she explained. 'If we can measure [Punctum's magnetic field] at more wavelengths or watch how it changes over time, we can start to figure out what powers Punctum and whether it links to known astrophysical objects.' 'Punctum shows us the universe can still surprise us in places we thought we understood well,' Shablovinskaia said. 'For me, it's a reminder that astronomy is far from finished; we're still just beginning to discover the full variety of cosmic objects out there.' The new research marks another strong example of multi-messenger astronomy, in which astronomers use different kinds of signals to investigate a single source. Recently, astronomers found an ultramassive black hole using gravitational lensing. In this case, the scientists studied a specific behavior of light—polarization—alongside more conventional methods to double-check their results.
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


Medscape
3 hours ago
- Medscape
Reclaiming Innovation in Patient-Centered Care
Medscape 2050: The Future of Medicine Summary: In this wide-ranging, deeply thoughtful commentary, Professor Christina Pagel, professor of operational research at University College London, underscores why data and AI, while transformative, are not silver bullets for modern healthcare challenges. Drawing from decades of experience working directly with clinicians, Pagel illustrates how collaborative, multidisciplinary environments drive more meaningful innovation than technology alone. She cautions against overreliance on AI, noting its limitations in upstream determinants of health and long-term outcomes. Instead, Pagel champions a model of medicine that prioritizes well-being, long-term survival, and access to care — especially for populations often ignored by traditional metrics and research, such as women with chronic menstrual pain. From clean water access to systemic underinvestment in "unsexy" conditions, Pagel's insights invite a critical rethinking of how medicine should evolve: not by replacing human judgment with algorithms, but by strengthening the diverse human networks that define healthcare's most effective interventions. Key Takeaways: